From Sweta Jaiswal, FRM: The biotech industry has kept its promise for solid returns so far. The rally in some major biotechnology indexes reflects the same. In this context, the NASDAQ Biotechnology Index has returned 17.6% year to date. Following the trend, S&P Biotechnology Select Industry Index has returned around 29%.
From ETF Channel Staff: Investors are actually buying and selling ”units”. These ”units” can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many […]
From Annie Pei: Biotech’s looking like a healthy bet these days.
From Chris Kimble: The chart below looks at Bio-Tech ETF (XBI) over the past three years.
From Dana Lyons: A popular biotech ETF is testing potentially formidable resistance on its chart.
From Zacks: The S&P 500’s bull market has just turned nine. On this very day, nine years ago, stocks bottomed out only to log an amazing recovery from the deepest recession since the Great Depression.
From Contrarian Outlook: If you’re like most folks, you probably think it’s tough for any fund to beat the S&P 500, especially in a year when the index jumped some 15%.
From Chris Kimble: Biotech used to be an upside leader over the broad market coming off the 2009 lows. Biotech then officially gave up its leadership back in 2015, where it peaked and started underperforming the broad market.
From Moby Waller: A huge amount of money goes into passive stock market tracking these days, through the S&P 500 Index (SPY) and other major U.S. indexes (DIA) (QQQ) (IWM). This strategy has done well in general in recent years and has gained popularity, particularly in retirement-type accounts.
From Sound Dollar Campaign: During the presidential campaign, the high price of prescription drugs became a blistering issue. At the same time, the Mylan/EpiPen scandal broke.
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) was on the decline this morning, after Donald Trump’s TIME Person of the Year profile revealed that the president-elect likely won’t be the bullish force for drug companies many thought he’d be.
The iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB) has recovered nicely from its yearly lows, and there’s reason to believe that more gains are on the horizon as well.
From Gary Savage: Today’s chart of the day focuses on a well-known biotech ETF, the SPDR S&P Biotech ETF (NYSE:XBI), which is threatening to break out even further to the upside.
From Zacks Research: The biotech sector has had a rough start to the year with the NASDAQ Biotechnology Index declining approximately 16% year-to-date. Sector-specific issues like increasing political and media focus on high price tags for new drugs and the changing competitive scenario have been weighing on biotech stocks over the last few quarters.